Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

New to the U.K. market: ophthalmic steroid from Alcon causes less IOP elevation

Dec. 16, 1999

AEterna presents promising phase I data for AE-941 in AMD

Dec. 13, 1999

Cambridge NeuroScience and Allergan extend ophthalmic research collaboration

Dec. 9, 1999

Projected enrollment exceeded in Miravant's phase III AMD trials

Dec. 8, 1999

Ciba Vision licenses Destiny's photodynamic therapy technology

Dec. 6, 1999

FDA advisory panel recommends approval of Visudyne therapy for wet AMD

Nov. 18, 1999

Ciba Vision introduces ocular formulation of lomefloxacin in U.K.

Nov. 15, 1999

Visudyne submitted for marketing approval in Canada

Nov. 8, 1999

Mycophenolate mofetil in the treatment of refractory uveitis

Oct. 28, 1999

AGN-192024 is better than latanoprost for lowering diurnal IOP

Oct. 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...